Date: 2017-05-02
Type of information: Clinical trial authorisation
phase:
Announcement: clinical trial authorization
Company: Oramed Pharmaceuticals (Israel)
Product: oral leptin capsule
Action mechanism: hormone/protein. Leptin, sometimes called the obesity, fat or satiety hormone, is a protein that is produced in fat cells located in adipose tissues and sends signals to the hypothalamus in the brain. Leptin helps to regulate and alter long-term food intake and energy expenditure. Leptin helps to inhibit hunger and regulate energy balance. Although leptin reduces appetite, obese individuals generally exhibit a higher concentration of leptin in their blood than normal weight individuals. These people show resistance to leptin, similar to resistance of insulin in type 2 diabetes. Leptin has additionally been shown to suppress glucagon secretion and improve glucose levels in type 1 diabetes.
Disease: obesity
Therapeutic area: Metabolic diseases
Country:
Trial details:
Latest news: • On May 2, 2017, Oramed Pharmaceuticals announced that based on positive preclinical data, the company is developing a new drug candidate, a weight loss treatment in the form of an oral leptin capsule. Leptin, also known as the “obesity hormone” is a protein that regulates hunger. According to Grand View Research, the overall obesity market is expected to reach $15.6 billion in 2024. Israel’s Ministry of Health has approved Oramed’s commencement of a proof of concept single dose study for its oral leptin drug candidate to evaluate its pharmacokinetic and pharmacodynamics (glucagon reduction) in ten type 1 diabetic patients.
